Alnylam awaits FDA decisions on Amvuttra & Fitusiran next month, poised to boost revenue, profitability, and share growth.

Sanofi announces buy back of shares from L’Oréal Paris, February 3, 2025. Sanofi today announces the acquisition of 2.3% of its shares from long-standing shareholder L’Oréal. This transaction is part ...

Sanofi has purchased 2.3% of its shares from L'Oréal SA as part of its share repurchase program. The €3 billion deal involves acquiring 29.6 million shares at €101.50 each, with cancellation expected ...

Paris: Sanofi has announced the acquisition of 2.3% of its shares from long-standing shareholder L’Oréal. This transaction is ...

Sanofi announces buy back of shares from L'Oréal Paris, February 3, 2025. Sanofi today announces the acquisition of 2.3% of its shares from long-standing shareholder L'Oréal. This transaction is part ...

Sanofi announced the acquisition of 2.3% of its shares from L'Oréal. This transaction is part of share buyback program announced on ...

Analyst Molly Wylenzek from Jefferies maintained a Hold rating on L’Oreal (0NZM – Research Report) and keeping the price target at ...

Sanofi today announces the acquisition of 2.3% of its shares from long-standing shareholder L’Oréal. This transaction is part of Sanofi’s share buyback program announced on January 30, 2025. It is ...

In other deals, Linklaters, Willkie and Latham are advising as PAI Partners negotiates to buy a stake in Alvest, a France-based provider of ground support equipment for airports, in a deal worth an ...

The deal will diversify the French beauty giant’s funding sources at a time when the industry is undergoing a slowdown.